HDC Atlas Clinic has launched the "GLP1.com Membership" service, and we've seen a huge increase in access (number of impressions, etc.) and a surge in the number of applications (see Figure 1 below) . However, please note that when entering your GLP1.com membership code, please enter your Prime Service Code in half-width alphanumeric characters (see Figures 2 and 3 below for reference).

The sudden increase in visits seems to reflect the need for proper treatment of Zepbound. It's not a problem to switch from other hospitals. Some patients who were prescribed Zepbound at other hospitals but didn't receive sufficient explanations have decided to switch to our hospital. Incidentally, as of July 2025, we have received verbal reports from pharmaceutical companies that our use of Zepbound and Manjaro (i.e., tirzepatide) is now far and away the most prescribed in Japan! (Is that true? lol) We will confirm the correct rankings and report back at a later date.

In particular, we have already achieved outstanding results not only in obesity treatment, but also in our core business of diabetes treatment. The HbA1c of our outpatient diabetic patients is generally below 6.5%. Compared to the results of other hospitals, our blood sugar control results are by far superior. This is likely due to the excellent use of tirzepatide (Manjaro and Zepbound). Please use this information as a reference if you are considering switching from Plaobes to Zepbound in the future. (Please refer to Figure 4 below.)